Johnson & Johnson (JNJ): FY25 Q3 earnings call, Oct 14, 2025
No Kalshi or Polymarket word markets were listed for Johnson & Johnson’s Oct 14, 2025 earnings call (FY25 Q3). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
6 matches for “Caplyta”; 4 quoted, at least 25 words apart.
…strengthened by this year's acquisition of intracellular therapies, with FDA approval for CAPLYTA in major depressive disorder anticipated soon. CAPLYTA is already FDA approved for…
…an impressive 60.8% driven by continued strong demand from physicians and patients. CAPLYTA, which was acquired in Q2 as part of the Intracellular acquisition, delivered…
…basis points driven by increased investment in the recent intracellular acquisition for CAPLYTA and promotional spend across the Innovative Medicine business, partially offset by expense…
…for subcutaneous Ribrovant for non-small cell lung cancer, as well as for CAPLYTA in adjunctive major depressive disorder. We recently filed for a label expansion…
Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2025-10-14:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2025-10-14:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP